Overview

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Venetoclax